CryositeASX:CTE +8.49%51 OCF Margin % is 14.76% as of Dec. 2025, which is 13% above its 10-year median of 13.07. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). Among 204 Medical Diagnostics & Research companies, Cryosite ranks better than 66.67% on this metric.
The historical rank and industry rank for Cryosite's OCF Margin % or its related term are showing as below:
ASX:CTE'
s OCF Margin % Range Over the Past 10 Years
Min: -8.19 Med: 13.07 Max: 21.75
Current: 13.62
During the past 13 years, the highest OCF Margin % of Cryosite was 21.75%. The lowest was -8.19%. And the median was 13.07%.
ASX:CTE's OCF Margin % is ranked better than 66.67% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.755
vs ASX:CTE: 13.62
Cryosite OCF Margin % Related Terms
Cryosite OCF Margin % Historical Data
* Premium members only.
The historical data trend for Cryosite's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Cryosite's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Cryosite's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a OCF Margin % of 14.76% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cryosite and its competitors. This is 13% above median its historical median of 13.07. According to the industry distribution chart, Cryosite ranks #68 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 33.3%.
Is Cryosite's OCF Margin % too high?
Cryosite's current OCF Margin % of 14.76% is 13% above median its 10-year median of 13.07. The Medical Diagnostics & Research industry median OCF Margin % is 4.76. Cryosite's value of 14.76% is 210.4% above this industry median. Based on the distribution chart, Cryosite ranks #68 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #68 out of 204 companies for OCF Margin %. This puts Cryosite in the upper half of its industry. The industry median OCF Margin % is 4.76. Cryosite's value of 14.76% is 210.4% above this benchmark. While the company's 10-year median is 13.07 vs. the industry median of 4.76, Cryosite has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.76, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryosite's current OCF Margin % of 14.76% is 210.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cryosite and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current OCF Margin % is 14.76%, which is 13% above median its own 10-year median of 13.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current OCF Margin % is 14.76%, which is 13% above median its 10-year median of 13.07 and 210.4% above the Medical Diagnostics & Research industry median of 4.76. Cryosite's overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current OCF Margin % is 14.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
OCF Margin %: 14.76% (13% above median its 10-year median of 13.07)
GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
Industry Position: 210.4% above the Medical Diagnostics & Research median (#68 of 204)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
